Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Induced Remission in CIDP
NCT06714838Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Amsterdam University Medical Center. Started Oct 2024; status: recruiting.
02
Drugs
rituximab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT06714838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714838.